Company

About 199 Bio

We are the reprogramming company: rewriting malignant and senescent cell behavior and measuring outcomes with real‑time diagnostics.

Mission

Make disease biology legible and reversible. We build therapies that reprogram malignant and senescent cell states while using diagnostics to verify change.

Team & Advisors

Boris Djordjevic

Founder & CEO

Founder of 199 group, translating reprogramming science into therapies and diagnostics.

LinkedIn Email

Antonia Schultze-Mosgau

Strategic Advisor

Longevity entrepreneur and scientist; Oxford All-Innovate award winner.

LinkedIn Email

Dr. Avi Roy

Strategic Advisor

Oxford biomedical scientist; president of Biogerontology Research Foundation.

LinkedIn Email

Dr. Qinghua Lyu

Chief Technical Officer

Drug development expert; leads chemical sciences and senolytic programs.

LinkedIn Email

Zico Yip

Chief Operating Officer

Operations lead across labs and manufacturing; fundraising and investments.

LinkedIn Email

IP Snapshot

Filed and issuing claims around engineered reprogramming factors, delivery methods, and diagnostic panels. Details in our investor data room.

For details, request data room access on the Investors page.